What sector does Glaxosmithkline Pharma Lt belong to?

Glaxosmithkline Pharma Lt operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of GLAXO?

As of the latest available quote, GLAXO traded at ₹2,828.40. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of GLAXO?

Glaxosmithkline Pharma Lt has a price-to-earnings (P/E) ratio of about 44.85. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of GLAXO?

The market capitalisation of Glaxosmithkline Pharma Lt is approximately ₹47,915 Cr.

Is Glaxosmithkline Pharma Lt profitable?

For its latest reported financial year, Glaxosmithkline Pharma Lt recorded a net profit margin of about 27.11%.

Does GLAXO pay a dividend?

Glaxosmithkline Pharma Lt does not currently show a dividend yield in our data.

What is the return on equity (ROE) of GLAXO?

Glaxosmithkline Pharma Lt has a return on equity (ROE) of about 45.60%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of GLAXO?

Over the past 52 weeks, GLAXO has traded between a low of ₹2,088.10 and a high of ₹3,120.70.

Glaxosmithkline Pharma Lt

GLAXO NSE Healthcare Pharmaceuticals

Nifty 500 Midcap 150 LargeMid 250

₹2,828.40

-0.44%

Delayed · cached 15 min

Fair value analysis

GLAXO

Glaxosmithkline Pharma Lt

₹2,840.90

Close used for this calculation

₹1,617.41Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

63/100

Profitability23/25

Returns10/25

Balance Sheet21/25

Efficiency9/25

Growth12/25

Good

Quality radar

Consensus fair value

₹1,617.41

Above FV

▼ -43.1% against the close used

Model range ₹433.91 – ₹3,098.85

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹433.91Fair value₹1,617.41Bull₹3,098.85

FairClose

52-week traded range

52W low ₹2,103.2052W high ₹3,106.40

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Glaxosmithkline Pharma Lt closed at ₹2,840.90, 75.6% above the consensus fair value of ₹1,617.41 drawn from 9 valuation models.

Financial DNA score 63/100 — Good. P/E of 45.5x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹1,023.87

-64.0%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹433.91

-84.7%

√(22.5 × EPS × BVPS)

EPS=61.15, BVPS=136.84 · outside Graham range (P/E 45.5, P/B 20.8) — asset-light, treat as a rough floor

P/E Fair Value

₹2,183.06

-23.2%

EPS × 35.7x (sector P/E)

EPS=61.15, Sector P/E=35.7x

Peter Lynch (PEG)

₹1,180.20

-58.5%

EPS × Growth% (PEG = 1 is fair)

EPS=61.15, g=19.3%

EV/EBITDA

₹1,465.48

-48.4%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=13.75B

Dividend Discount (DDM)

₹3,098.85

+9.1%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=57.39, r=10%, g=8%

Book Value (P/B)

₹1,354.76

-52.3%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=136.84, ROE=45.6%, g=6%, r=10%

Reverse DCF

₹2,840.90

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 18.5% | Historical: 19.3%

Margin of Safety

₹910.21

-68.0%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=1213.61, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer